Back to Screener

Healthcare

Alnylam Pharmaceuticals, Inc.(ALNY)

Live Price

Offline

$282.85

-2.26% today

Window Change

-7.91%

Window

May 29, 2026 โ†’ Jun 18, 2026

Market Cap
$39.75B
Revenue Growth
+65.2%
EPS Growth
+209.6%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 15 bars ยท May 29, 2026 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Alnylam Pharmaceuticals, Inc. (ALNY) is a Healthcare stock with a market cap of $39.75B. The stock last traded around $282.85 and down 7.9% across the available one-year price window (May 29, 2026 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of +65.2%, EPS growth of +209.6%, a dividend yield of 0.0%. What stands out right now is revenue +65.2%, EPS +209.6%, free cash flow +1192.7% with operating margin 17.5% and ROIC 19.7%. Valuation already assumes a fairly strong business story at P/E 68.6 and price/sales 9.3. Stock Foundry combines ALNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+65.2% vs +7.6% peer median

Operating Margin

Near sector median

+17.5% vs +19.4% peer median

P/E

Above sector median

68.6 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 7, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +65.2% and EPS at +209.6%, with operating margin around 17.5%.

Benchmark Edge

ALNY vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ALNY

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ALNY Max Drawdown

-8.41%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ALNY and SPY.

Calendar-year return history is still loading or unavailable.
AL

Company Overview

Alnylam Pharmaceuticals, Inc.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
68.6
EV/EBITDA
64.1
Price/Sales
9.3
Price/Book
36.8

Growth

Revenue
+65.2%
EPS
+209.6%
Free Cash Flow
+1192.7%

Profitability

Gross Margin
80.9%
Operating Margin
17.5%
Net Margin
13.5%
ROE
98.3%
ROIC
19.7%

Balance Sheet

Debt/Equity
1.18
Current Ratio
3.13

Earnings Reports

๐Ÿ“… Last reportedMay 7, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 7, 26
โ€”
Est 1.50
โ€”
โ€”
Est 1127326.0B
โ€”
โ€”
Feb 12, 26
โœ—
0.82
Est 1.16
-29.3%
1097033.0B
Est 1149111.0B
-4.5%
โ€”
Oct 30, 25
โœ“
2.90
Est 0.56
+416.9%
1249026.0B
Est 959400.7B
+30.2%
โ€”
Jul 31, 25
โœ“
0.32
Est -0.54
+158.8%
773689.0B
Est 662872.2B
+16.7%
โ€”
May 1, 25
โœ“
-0.01
Est -0.89
+98.9%
594189.0B
Est 585142.2B
+1.6%
โ€”
Feb 13, 25
โœ“
0.06
Est -0.62
+109.7%
593166.0B
Est 582606.2B
+1.8%
โ€”
Oct 31, 24
โœ“
-0.50
Est -0.92
+45.5%
500919.0B
Est 532911.7B
-6.0%
โ€”
Aug 1, 24
โœ“
0.56
Est -1.07
+152.3%
659825.0B
Est 447220.3B
+47.5%
โ€”
May 2, 24
โœ“
-0.16
Est -1.12
+85.7%
494333.0B
Est 428005.8B
+15.5%
โ€”
Feb 15, 24
โœ“
-1.10
Est -1.20
+8.3%
439718.0B
Est 442900.0B
-0.7%
โ€”
Nov 2, 23
โœ“
1.15
Est -1.34
+185.8%
750530.0B
Est 401030.0B
+87.2%
โ€”
Aug 3, 23
โœ—
-2.21
Est -1.72
-28.5%
318754.0B
Est 350510.0B
-9.1%
โ€”
May 4, 23
โœ“
-1.40
Est -1.97
+28.9%
319290.0B
Est 312260.0B
+2.3%
โ€”
Feb 23, 23
โœ“
-1.68
Est -2.13
+21.1%
335035.0B
Est 313134.6B
+7.0%
โ€”
Oct 27, 22
โœ—
-3.32
Est -1.86
-78.5%
264306.0B
Est 291658.2B
-9.4%
โ€”
Jul 28, 22
โœ—
-2.29
Est -1.62
-41.4%
224818.0B
Est 255557.7B
-12.0%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks